BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30274702)

  • 1. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
    Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Tan WP; Kotamarti S; Chen E; Mahle R; Arcot R; Chang A; Ayala A; Michael Z; Seguier D; Polascik TJ
    Cancer; 2022 Nov; 128(21):3824-3830. PubMed ID: 36107496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
    Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
    Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre.
    Wenske S; Quarrier S; Katz AE
    Eur Urol; 2013 Jul; 64(1):1-7. PubMed ID: 22840351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
    J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
    Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
    J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence.
    De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE
    BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.
    De Marini P; Cazzato RL; Garnon J; Tricard T; Koch G; Tsoumakidou G; Ramamurthy N; Lang H; Gangi A
    Br J Radiol; 2019 May; 92(1097):20180965. PubMed ID: 30845821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of biochemical success following primary whole gland prostate cryoablation.
    Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
    J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer.
    Tan WP; Kotamarti S; Ayala A; Mahle R; Chen E; Arcot R; Chang A; Michael Z; Seguier D; Polascik TJ
    Eur Urol Oncol; 2023 Jun; 6(3):289-294. PubMed ID: 36890104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
    Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
    Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.
    Bossier R; Sanguedolce F; Territo A; Vanacore D; Martínez C; Regis F; Gallioli A; Mercade A; Mosquera L; Aumatell J; Balana J; Carlderon J; Huguet J; Gaya JM; Palou J; Breda A
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):172-178. PubMed ID: 32033834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal cryosurgical ablation of the prostate: a single institute's perspective.
    Hale Z; Miyake M; Palacios DA; Rosser CJ
    BMC Urol; 2013 Jan; 13():2. PubMed ID: 23311921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
    Sooriakumaran P; Haendler L; Nyberg T; Gronberg H; Nilsson A; Carlsson S; Hosseini A; Adding C; Jonsson M; Ploumidis A; Egevad L; Steineck G; Wiklund P
    Eur Urol; 2012 Nov; 62(5):768-74. PubMed ID: 22633365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System.
    Safavy S; Jabaji RB; Lu SM; Slezak JM; Cosmatos HA; Williams SG; Finley DS
    Perm J; 2019; 23():. PubMed ID: 31050644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
    Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
    BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.